{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:20:20Z","timestamp":1794331220839,"version":"4.9.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41584-020-0374-8","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T14:04:05Z","timestamp":1581602645000},"page":"167-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":227,"title":["Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology"],"prefix":"10.1038","volume":"16","author":[{"given":"Jasper C. A.","family":"Broen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"374_CR1","unstructured":"Nobel Media AB 2020. The nobel prize in physiology or medicine 1988. NobelPrize.Org. https:\/\/www.nobelprize.org\/prizes\/medicine\/1988\/summary\/ (2020)."},{"key":"374_CR2","unstructured":"Alsberg, C. L. & Black F. in Contribution to the study of maize deterioration; biochemical and toxicological investigations of Penicillium puberulum and Penicillium stoloniferum (Trieste, 1913)."},{"key":"374_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2893.1999.00163.x","volume":"6","author":"ZJ Gong","year":"1999","unstructured":"Gong, Z. J. et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J. Viral Hepat. 6, 229\u2013236 (1999).","journal-title":"J. Viral Hepat."},{"key":"374_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1042\/bj0390398","volume":"39","author":"EP Abraham","year":"1945","unstructured":"Abraham, E. P. The effect of mycophenolic acid on the growth of Staphylococcus aureus in heart broth. Biochem. J. 39, 398\u2013404 (1945).","journal-title":"Biochem. J."},{"key":"374_CR5","first-page":"57","volume":"30","author":"AC Allison","year":"1991","unstructured":"Allison, A. C. & Eugui, E. M. Immunosuppressive and long-acting anti-inflammatory activity of mycophenolic acid and derivative, RS-61443. Br. J. Rheumatol. 30, 57\u201361 (1991).","journal-title":"Br. J. Rheumatol."},{"key":"374_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/1523-1747.ep12610346","volume":"65","author":"EL Jones","year":"1975","unstructured":"Jones, E. L. et al. Treatment of psoriasis with oral mycophenolic acid. J. Invest. Dermatol. 65, 537\u2013542 (1975).","journal-title":"J. Invest. Dermatol."},{"key":"374_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","volume":"348","author":"JJ Lipsky","year":"1996","unstructured":"Lipsky, J. J. Mycophenolate mofetil. Lancet 348, 1357\u20131359 (1996).","journal-title":"Lancet"},{"key":"374_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham, R. E., Nicholls, A. J. & Kamm, B. R. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34, 429\u2013455 (1998).","journal-title":"Clin. Pharmacokinet."},{"key":"374_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/01.ftd.0000194504.62892.b2","volume":"28","author":"RM Van Hest","year":"2006","unstructured":"Van Hest, R. M. et al. Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. Ther. Drug Monit. 28, 31\u201334 (2006).","journal-title":"Ther. Drug Monit."},{"key":"374_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.clpt.2005.06.007","volume":"78","author":"DR Kuypers","year":"2005","unstructured":"Kuypers, D. R. et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78, 351\u2013361 (2005).","journal-title":"Clin. Pharmacol. Ther."},{"key":"374_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1177\/0091270011412968","volume":"52","author":"MG Kees","year":"2012","unstructured":"Kees, M. G. et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J. Clin. Pharmacol. 52, 1265\u20131272 (2012).","journal-title":"J. Clin. Pharmacol."},{"key":"374_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00007691-200002000-00005","volume":"22","author":"HU Meier-Kriesche","year":"2000","unstructured":"Meier-Kriesche, H. U. et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther. Drug Monit. 22, 27\u201330 (2000).","journal-title":"Ther. Drug Monit."},{"key":"374_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/0961203312469261","volume":"22","author":"GM Daleboudt","year":"2013","unstructured":"Daleboudt, G. M. et al. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus 22, 171\u2013179 (2013).","journal-title":"Lupus"},{"key":"374_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/FTD.0000000000000031","volume":"36","author":"S Alexander","year":"2014","unstructured":"Alexander, S. et al. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther. Drug Monit. 36, 423\u2013432 (2014).","journal-title":"Ther. Drug Monit."},{"key":"374_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","volume":"17","author":"JT Ransom","year":"1995","unstructured":"Ransom, J. T. Mechanism of action of mycophenolate mofetil. Ther. Drug Monit. 17, 681\u2013684 (1995).","journal-title":"Ther. Drug Monit."},{"key":"374_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s004670050359","volume":"11","author":"M Suthanthiran","year":"1997","unstructured":"Suthanthiran, M. & Strom, T. B. Immunoregulatory drugs: mechanistic basis for use in organ transplantation. Pediatr. Nephrol. 11, 651\u2013657 (1997).","journal-title":"Pediatr. Nephrol."},{"key":"374_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0961203315570685","volume":"24","author":"Q Tang","year":"2015","unstructured":"Tang, Q. et al. Mycophenolic acid upregulates miR-142-3P\/5P and miR-146a in lupus CD4+T cells. Lupus 24, 935\u2013942 (2015).","journal-title":"Lupus"},{"key":"374_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-3083.2010.02383.x","volume":"71","author":"L Li","year":"2010","unstructured":"Li, L., Chen, X. P. & Li, Y. J. MicroRNA-146a and human disease. Scand. J. Immunol. 71, 227\u2013231 (2010).","journal-title":"Scand. J. Immunol."},{"key":"374_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.clim.2015.03.005","volume":"158","author":"Y Yang","year":"2015","unstructured":"Yang, Y. et al. The effect of mycophenolic acid on epigenetic modifications in lupus CD4+T cells. Clin. Immunol. 158, 67\u201376 (2015).","journal-title":"Clin. Immunol."},{"key":"374_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.imlet.2013.07.005","volume":"153","author":"B Zhang","year":"2013","unstructured":"Zhang, B. et al. The CD40\/CD40L system: a new therapeutic target for disease. Immunol. Lett. 153, 58\u201361 (2013).","journal-title":"Immunol. Lett."},{"key":"374_CR21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.autrev.2016.07.025","volume":"15","author":"A Morales-C\u00e1rdenas","year":"2016","unstructured":"Morales-C\u00e1rdenas, A. et al. Pulmonary involvement in systemic sclerosis. Autoimmun. Rev. 15, 1094\u20131108 (2016).","journal-title":"Autoimmun. Rev."},{"key":"374_CR22","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/j.1600-6143.2008.02322.x","volume":"8","author":"C Morath","year":"2008","unstructured":"Morath, C. et al. Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivo. Am. J. Transplant. 8, 1786\u20131797 (2008).","journal-title":"Am. J. Transplant."},{"key":"374_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1523-1755.2000.00140.x","volume":"58","author":"C Badid","year":"2000","unstructured":"Badid, C. et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 58, 51\u201361 (2000).","journal-title":"Kidney Int."},{"key":"374_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2249.2004.02488.x","volume":"136","author":"C Johnsson","year":"2004","unstructured":"Johnsson, C., Gerdin, B. & Tufveson, G. Effects of commonly used immunosuppressants on graft-derived fibroblasts. Clin. Exp. Immunol. 136, 405\u2013412 (2004).","journal-title":"Clin. Exp. Immunol."},{"key":"374_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/01.TP.0000101822.50960.AB","volume":"77","author":"A Azzola","year":"2004","unstructured":"Azzola, A. et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 77, 275\u2013280 (2004).","journal-title":"Transplantation"},{"key":"374_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2230.2011.04201.x","volume":"37","author":"M Ozgen","year":"2012","unstructured":"Ozgen, M. et al. Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin. Exp. Dermatol. 37, 48\u201354 (2012).","journal-title":"Clin. Exp. Dermatol."},{"key":"374_CR27","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.ajpath.2011.06.001","volume":"179","author":"S Piera-Velazquez","year":"2011","unstructured":"Piera-Velazquez, S., Li, Z. & Jimenez, S. A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. 179, 1074\u20131080 (2011).","journal-title":"Am. J. Pathol."},{"key":"374_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-019-0227-x","volume":"14","author":"RD Wright","year":"2019","unstructured":"Wright, R. D., Dimou, P., Northey, S. J. & Beresford, M. W. Mesangial cells are key contributors to the fibrotic damage seen in the lupus nephritis glomerulus. J. Inflamm. 14, 22 (2019).","journal-title":"J. Inflamm."},{"key":"374_CR29","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/S0041-1345(98)01952-6","volume":"31","author":"W Wang","year":"1999","unstructured":"Wang, W., Mo, S. & Chan, L. Mycophenolic acid inhibits PDGF-induced osteopontin expression in rat mesangial cells. Transpl. Proc. 31, 1176\u20131177 (1999).","journal-title":"Transpl. Proc."},{"key":"374_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1046\/j.1523-1755.2002.00514.x","volume":"62","author":"I Dubus","year":"2002","unstructured":"Dubus, I. et al. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int. 62, 857\u2013867 (2002).","journal-title":"Kidney Int."},{"key":"374_CR31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3892\/mmr.2014.2861","volume":"11","author":"X Zhou","year":"2015","unstructured":"Zhou, X., Workeneh, B., Hu, Z. & Li, R. Effect of immunosuppression on the human mesangial cell cycle. Mol. Med. Rep. 11, 910\u2013916 (2015).","journal-title":"Mol. Med. Rep."},{"key":"374_CR32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","volume":"138","author":"M Hinchcliff","year":"2018","unstructured":"Hinchcliff, M. et al. Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin. J. Invest. Dermatol. 138, 1301\u20131310 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"374_CR33","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TMet Chan","year":"2000","unstructured":"Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343, 1156\u20131162 (2000).","journal-title":"N. Engl. J. Med."},{"key":"374_CR34","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","volume":"48","author":"CT Derk","year":"2009","unstructured":"Derk, C. T. et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 48, 1595\u20131599 (2009).","journal-title":"Rheumatology"},{"key":"374_CR35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/art.20240","volume":"51","author":"CA Langford","year":"2004","unstructured":"Langford, C. A., Talar-Williams, C. & Sneller, M. C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener\u2019s granulomatosis. Arthritis Rheum. 51, 278\u2013283 (2004).","journal-title":"Arthritis Rheum."},{"key":"374_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia, V. & Harisdangkul, V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 44, 386\u2013389 (2005).","journal-title":"Rheumatology"},{"key":"374_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J Rowin","year":"2006","unstructured":"Rowin, J. et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 66, 1245\u20131247 (2006).","journal-title":"Neurology."},{"key":"374_CR38","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219\u20132228 (2005).","journal-title":"N. Engl. J. Med."},{"key":"374_CR39","first-page":"39","volume":"38","author":"Z Touma","year":"2011","unstructured":"Touma, Z. et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and meta-analysis. J. Rheumatol. 38, 39\u201378 (2011).","journal-title":"J. Rheumatol."},{"key":"374_CR40","doi-asserted-by":"publisher","unstructured":"Henderson L. et al. Treatment for lupus nephritis. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD002922.pub3 (2012).","DOI":"10.1002\/14651858.CD002922.pub3"},{"key":"374_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/rheumatology\/ket429","volume":"53","author":"JR Maneiro","year":"2014","unstructured":"Maneiro, J. R. et al. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: a systematic review and meta-analysis. Rheumatology 53, 834\u2013838 (2014).","journal-title":"Rheumatology"},{"key":"374_CR42","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1093\/ndt\/gfr553","volume":"27","author":"MS Stoenoiu","year":"2012","unstructured":"Stoenoiu, M. S. et al. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol. Dial. Transpl. 27, 1924\u20131930 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"374_CR43","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros, J. et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann. Rheum. Dis. 76, 1575\u20131582 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"374_CR44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","volume":"70","author":"SC Palmer","year":"2017","unstructured":"Palmer, S. C. et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network mata-analysis of randomized trials. Am. J. Kidney Dis. 70, 324\u2013336 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"374_CR45","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","volume":"53","author":"E Ntatsaki","year":"2014","unstructured":"Ntatsaki, E. et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology 53, 2306\u20132309 (2014).","journal-title":"Rheumatology"},{"key":"374_CR46","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra, T. F. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304, 2381\u20132388 (2010).","journal-title":"JAMA"},{"key":"374_CR47","doi-asserted-by":"publisher","first-page":"i132","DOI":"10.1093\/ndt\/gfv061","volume":"30","author":"J Draibe","year":"2015","unstructured":"Draibe, J. et al. Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital. Nephrol. Dial. Transpl. 30, i132\u2013i137 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"374_CR48","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"Morganroth, P. A., Kreider, M. E. & Werth, V. P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 62, 1496\u20131501 (2010).","journal-title":"Arthritis Care Res."},{"key":"374_CR49","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","volume":"168","author":"LA Saketkoo","year":"2008","unstructured":"Saketkoo, L. A. & Espinoza, L. R. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch. Intern. Med. 168, 1718\u20131719 (2008).","journal-title":"Arch. Intern. Med."},{"key":"374_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1378\/chest.06-2861","volume":"133","author":"AJ Gerbino","year":"2008","unstructured":"Gerbino, A. J., Goss, C. H. & Molitor, J. A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133, 455\u2013460 (2008).","journal-title":"Chest"},{"key":"374_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLE II): a randomized controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708\u2013719 (2016).","journal-title":"Lancet Respir. Med."},{"key":"374_CR52","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann, E. R. et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 69, 1451\u20131460 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"374_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/acr.23282","volume":"70","author":"R Namas","year":"2018","unstructured":"Namas, R. et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res. 70, 439\u2013444 (2018).","journal-title":"Arthritis Care Res."},{"key":"374_CR54","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick, A. L. et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann. Rheum. Dis. 76, 1207\u20131218 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"374_CR55","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov (2020)."},{"key":"374_CR56","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03444805 (2019)."},{"key":"374_CR57","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03678987 (2018)."},{"key":"374_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02954939 (2019)."},{"key":"374_CR59","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01946880 (2019)."},{"key":"374_CR60","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02453997 (2017)."},{"key":"374_CR61","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar1861","volume":"8","author":"NJ Ganson","year":"2005","unstructured":"Ganson, N. J. et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 8, R12 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"374_CR62","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar4500","volume":"16","author":"MS Hershfield","year":"2014","unstructured":"Hershfield, M. S. et al. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res. Ther. 16, R63 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"374_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03303989 (2019)."},{"key":"374_CR64","first-page":"5","volume":"9","author":"FG Feturi","year":"2018","unstructured":"Feturi, F. G. et al. Mycophenolic acid for topical immunosuppression in vascularized composite allotransplantation: optimizing formulation and preliminary evaluation of bioavailability and pharmacokinetics. Front. Surg. 9, 5\u201320 (2018).","journal-title":"Front. Surg."},{"key":"374_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijpharm.2012.12.016","volume":"441","author":"HL Dugas","year":"2013","unstructured":"Dugas, H. L., Peters, J. I. & Williams, R. O. III Nebulization of mycophenolate mofetil inhalation suspension in rats: comparison with oral and pulmonary administration of Cellcept\u00ae. Int. J. Pharm. 441, 19\u201329 (2013).","journal-title":"Int. J. Pharm."},{"key":"374_CR66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1126\/science.2649979","volume":"244","author":"GB Elion","year":"1989","unstructured":"Elion, G. B. The purine path to chemotherapy. Science 244, 41\u201347 (1989).","journal-title":"Science"},{"key":"374_CR67","first-page":"47","volume":"8","author":"GB Elion","year":"1960","unstructured":"Elion, G. B., Callahan, S. W. & Hitchings, G. H. The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57\u2013323) in man. Cancer Chemother. Rep. 8, 47\u201352 (1960).","journal-title":"Cancer Chemother. Rep."},{"key":"374_CR68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3181\/00379727-99-24281","volume":"99","author":"R Schwartz","year":"1958","unstructured":"Schwartz, R., Stack, J. & Dameshek, W. Effect of 6-mercaptopurine on antibody production. Proc. Soc. Exp. Biol. Med. 99, 164\u2013167 (1958).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"374_CR69","first-page":"549","volume":"63","author":"TE Starzl","year":"1968","unstructured":"Starzl, T. E. et al. Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery. 63, 549\u2013563 (1968).","journal-title":"Surgery."},{"key":"374_CR70","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(64)91627-7","volume":"1","author":"IR MacKay","year":"1964","unstructured":"MacKay, I. R., Weiden, S. & Ungar, B. Treatment of active chronic hepatitis and lupoid hepatitis with 6-mercaptopurine and azathioprine. Lancet 1, 899\u2013902 (1964).","journal-title":"Lancet"},{"key":"374_CR71","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/03602538508991433","volume":"16","author":"KG Van Scoik","year":"1985","unstructured":"Van Scoik, K. G., Johnson, C. A. & Porter, W. R. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab. Rev. 16, 157\u2013174 (1985).","journal-title":"Drug Metab. Rev."},{"key":"374_CR72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/gut.39.1.63","volume":"39","author":"EC Van Os","year":"1996","unstructured":"Van Os, E. C. et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 39, 63\u201368 (1996).","journal-title":"Gut"},{"key":"374_CR73","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/1529-0131(199810)41:10<1858::AID-ART19>3.0.CO;2-8","volume":"41","author":"JN Stolk","year":"1998","unstructured":"Stolk, J. N. et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 41, 1858\u20131866 (1998).","journal-title":"Arthritis Rheum."},{"key":"374_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00007691-199402000-00002","volume":"16","author":"S Bergan","year":"1994","unstructured":"Bergan, S. et al. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther. Drug Monit. 16, 13\u201320 (1994).","journal-title":"Ther. Drug Monit."},{"key":"374_CR75","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/00007890-199205000-00016","volume":"53","author":"PR Chocair","year":"1992","unstructured":"Chocair, P. R. et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53, 1051\u20131056 (1992).","journal-title":"Transplantation"},{"key":"374_CR76","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1124\/jpet.109.154948","volume":"331","author":"EJ Jung","year":"2009","unstructured":"Jung, E. J. et al. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. J. Pharmacol. Exp. Ther. 331, 1005\u20131013 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"374_CR77","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI16432","volume":"111","author":"I Tiede","year":"2003","unstructured":"Tiede, I. et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111, 1133\u20131145 (2003).","journal-title":"J. Clin. Invest."},{"key":"374_CR78","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1182\/blood-2010-08-299438","volume":"116","author":"M Faroudi","year":"2010","unstructured":"Faroudi, M. et al. Critical roles for Rac GTPases in T-cell migration to and within lymph nodes. Blood. 116, 5536\u20135547 (2010).","journal-title":"Blood."},{"key":"374_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018329","volume":"6","author":"I Bertini","year":"2011","unstructured":"Bertini, I. et al. The anti-apoptotic Bcl-x(L) protein, a new piece in the puzzle of cytochrome c interactome. PLoS One 6, e18329 (2011).","journal-title":"PLoS One"},{"key":"374_CR80","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1172\/JCI200318384","volume":"111","author":"JS Maltzman","year":"2003","unstructured":"Maltzman, J. S. & Koretzky, G. A. Azathioprine: old drug, new actions. J. Clin. Invest. 111, 1122\u20131124 (2003).","journal-title":"J. Clin. Invest."},{"key":"374_CR81","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/MIB.0000000000000122","volume":"20","author":"G Marinkovi\u0107","year":"2014","unstructured":"Marinkovic\u00b4, G. et al. 6-Mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1. Inflamm. Bowel Dis. 20, 1487\u20131495 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"374_CR82","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.4049\/jimmunol.1302527","volume":"192","author":"G Marinkovi\u0107","year":"2014","unstructured":"Marinkovic\u00b4, G. et al. Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug. J. Immunol. 192, 4370\u20134378 (2014).","journal-title":"J. Immunol."},{"key":"374_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195524","volume":"13","author":"AC Hessels","year":"2018","unstructured":"Hessels, A. C. et al. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study. PLoS One 13, e0195524 (2018).","journal-title":"PLoS One"},{"key":"374_CR84","first-page":"233","volume":"14","author":"IE Tareyeva","year":"1980","unstructured":"Tareyeva, I. E., Shilov, E. M. & Gordovskaya, N. B. The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis. Clin. Nephrol. 14, 233\u2013237 (1980).","journal-title":"Clin. Nephrol."},{"key":"374_CR85","first-page":"535","volume":"10","author":"J Glas","year":"2005","unstructured":"Glas, J. et al. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur. J. Med. Res. 10, 535\u2013538 (2005).","journal-title":"Eur. J. Med. Res."},{"key":"374_CR86","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/gut.50.4.485","volume":"50","author":"AG Fraser","year":"2002","unstructured":"Fraser, A. G., Orchard, T. R. & Jewell, D. P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50, 485\u2013489 (2002).","journal-title":"Gut"},{"key":"374_CR87","first-page":"CD001461","volume":"4","author":"ME Suarez-Almazor","year":"2000","unstructured":"Suarez-Almazor, M. E., Spooner, C. & Belseck, E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 4, CD001461 (2000).","journal-title":"Cochrane Database Syst. Rev."},{"key":"374_CR88","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/sj.ki.5001630","volume":"70","author":"C Grootscholten","year":"2006","unstructured":"Grootscholten, C. et al. Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis: a randomized controlled trial. Kidney Int. 70, 732\u2013742 (2006).","journal-title":"Kidney Int."},{"key":"374_CR89","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36\u201344 (2003).","journal-title":"N. Engl. J. Med."},{"key":"374_CR90","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310\u2013317 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"374_CR91","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras, G. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971\u2013980 (2004).","journal-title":"N. Engl. J. Med."},{"key":"374_CR92","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/00005792-199711000-00006","volume":"76","author":"P Rahman","year":"1997","unstructured":"Rahman, P. et al. Cytotoxic therapy in systemic lupus erythematosus: experience from a single center. Medicine 76, 432\u2013437 (1997).","journal-title":"Medicine"},{"key":"374_CR93","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/art.1780400425","volume":"40","author":"V Hamuryudan","year":"1997","unstructured":"Hamuryudan, V. et al. Azathioprine in Beh\u00e7et\u2019s syndrome: effects on long-term prognosis. Arthritis Rheum. 40, 769\u2013774 (1997).","journal-title":"Arthritis Rheum."},{"key":"374_CR94","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/36.1.95","volume":"36","author":"G Jones","year":"1997","unstructured":"Jones, G., Crotty, M. & Brooks, P. Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br. J. Rheumatol. 36, 95\u201399 (1997).","journal-title":"Br. J. Rheumatol."},{"key":"374_CR95","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10067-004-1002-8","volume":"24","author":"E Benenson","year":"2005","unstructured":"Benenson, E. et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener\u2019s granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin. Rheumatol. 24, 251\u2013257 (2005).","journal-title":"Clin. Rheumatol."},{"key":"374_CR96","first-page":"1064","volume":"35","author":"A B\u00e9rezn\u00e9","year":"2008","unstructured":"B\u00e9rezn\u00e9, A. et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J. Rheumatol. 35, 1064\u20131072 (2008).","journal-title":"J. Rheumatol."},{"key":"374_CR97","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962\u20133970 (2006).","journal-title":"Arthritis Rheum."},{"key":"374_CR98","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03770663 (2018)."},{"key":"374_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-018-0433-3","volume":"11","author":"C Vuillard","year":"2018","unstructured":"Vuillard, C. et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study. Ann. Intensive Care 11, 87 (2018).","journal-title":"Ann. Intensive Care"},{"key":"374_CR100","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03543527 (2018)."},{"key":"374_CR101","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02356445 (2017)."},{"key":"374_CR102","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02954939 (2016)."},{"key":"374_CR103","doi-asserted-by":"publisher","first-page":"E711","DOI":"10.1002\/ijc.29209","volume":"136","author":"PA Dugu\u00e9","year":"2015","unstructured":"Dugu\u00e9, P. A. et al. Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study. Int. J. Cancer. 136, E711\u2013E719 (2015).","journal-title":"Int. J. Cancer."},{"key":"374_CR104","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/ajt.13863","volume":"16","author":"Z Jiyad","year":"2016","unstructured":"Jiyad, Z. et al. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am. J. Transplant. 16, 3490\u20133503 (2016).","journal-title":"Am. J. Transplant."},{"key":"374_CR105","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/DSS.0000000000001455","volume":"44","author":"JW Hagen","year":"2018","unstructured":"Hagen, J. W. & Pugliano-Mauro, M. A. Nonmelanoma skin cancer risk in patients with inflammatory bowel disease undergoing thiopurine therapy: a systematic review of the literature. Dermatol. Surg. 44, 469\u2013480 (2018).","journal-title":"Dermatol. Surg."},{"key":"374_CR106","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3389\/fphar.2018.01107","volume":"9","author":"SZ Lim","year":"2018","unstructured":"Lim, S. Z. & Chua, E. W. Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring. Front. Pharmacol. 9, 1107 (2018).","journal-title":"Front. Pharmacol."},{"key":"374_CR107","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino, T. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. 40, 1256\u20131265 (1987).","journal-title":"J. Antibiot."},{"key":"374_CR108","first-page":"36","volume":"19","author":"T Kino","year":"1987","unstructured":"Kino, T. et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transpl. Proc. 19, 36\u201339 (1987).","journal-title":"Transpl. Proc."},{"key":"374_CR109","first-page":"829","volume":"21","author":"T Ochiai","year":"1989","unstructured":"Ochiai, T. et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. Transpl. Proc. 21, 829\u2013832 (1989).","journal-title":"Transpl. Proc."},{"key":"374_CR110","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(89)91014-3","volume":"2","author":"TE Starzl","year":"1989","unstructured":"Starzl, T. E. et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 2, 1000\u20131004 (1989).","journal-title":"Lancet"},{"key":"374_CR111","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003495-199754060-00009","volume":"54","author":"CM Spencer","year":"1997","unstructured":"Spencer, C. M., Goa, K. L. & Gillis, J. C. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54, 925\u2013975 (1997).","journal-title":"Drugs"},{"key":"374_CR112","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2165\/00003495-199346040-00009","volume":"46","author":"DH Peters","year":"1993","unstructured":"Peters, D. H. et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46, 746\u2013794 (1993).","journal-title":"Drugs"},{"key":"374_CR113","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","volume":"19","author":"M Yu","year":"2018","unstructured":"Yu, M. et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr. Drug Metab. 19, 513\u2013522 (2018).","journal-title":"Curr. Drug Metab."},{"key":"374_CR114","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/j.1600-6143.2005.00844.x","volume":"5","author":"W Lemahieu","year":"2005","unstructured":"Lemahieu, W. et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am. J. Transplant. 5, 1383\u20131391 (2005).","journal-title":"Am. J. Transplant."},{"key":"374_CR115","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/embo-reports\/kvd090","volume":"1","author":"S Matsuda","year":"2000","unstructured":"Matsuda, S. et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep. 1, 428\u2013434 (2000).","journal-title":"EMBO Rep."},{"key":"374_CR116","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1002\/j.1460-2075.1994.tb06940.x","volume":"13","author":"ME Cardenas","year":"1994","unstructured":"Cardenas, M. E. et al. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. EMBO J. 13, 5944\u20135957 (1994).","journal-title":"EMBO J."},{"key":"374_CR117","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/357695a0","volume":"357","author":"NA Clipstone","year":"1992","unstructured":"Clipstone, N. A. & Crabtree, G. R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357, 695\u2013697 (1992).","journal-title":"Nature"},{"key":"374_CR118","doi-asserted-by":"publisher","first-page":"11205","DOI":"10.1073\/pnas.92.24.11205","volume":"92","author":"KT Shaw","year":"1995","unstructured":"Shaw, K. T. et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc. Natl Acad. Sci. USA 92, 11205\u201311209 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"374_CR119","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1126\/science.2497518","volume":"244","author":"B Hoyos","year":"1989","unstructured":"Hoyos, B. et al. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science 244, 457\u2013460 (1989).","journal-title":"Science"},{"key":"374_CR120","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/j.1460-2075.1994.tb06329.x","volume":"13","author":"B Frantz","year":"1994","unstructured":"Frantz, B. et al. Calcineurin acts in synergy with PMA to inactivate I \u03ba B\/MAD3, an inhibitor of NF-\u03ba B. EMBO J. 13, 861\u2013870 (1994).","journal-title":"EMBO J."},{"key":"374_CR121","doi-asserted-by":"publisher","first-page":"12378","DOI":"10.1074\/jbc.273.20.12378","volume":"273","author":"S Matsuda","year":"1998","unstructured":"Matsuda, S. et al. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK\/JNK signaling pathways sensitive to cyclosporin A. J. Biol. Chem. 273, 12378\u201312382 (1998).","journal-title":"J. Biol. Chem."},{"key":"374_CR122","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/00007890-199902270-00021","volume":"67","author":"A Khanna","year":"1999","unstructured":"Khanna, A. et al. Tacrolimus induces increased expression of transforming growth factor-\u03b21 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 67, 614\u2013619 (1999).","journal-title":"Transplantation"},{"key":"374_CR123","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00007890-199802150-00003","volume":"65","author":"GT Shin","year":"1998","unstructured":"Shin, G. T. et al. In vivo expression of transforming growth factor-\u03b21 in humans: stimulation by cyclosporine. Transplantation 65, 313\u2013318 (1998).","journal-title":"Transplantation"},{"key":"374_CR124","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1046\/j.1523-1755.2002.00668.x","volume":"62","author":"A Khanna","year":"2002","unstructured":"Khanna, A. et al. Expression of TGF-\u03b2 and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int. 62, 2257\u20132263 (2002).","journal-title":"Kidney Int."},{"key":"374_CR125","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10067-015-2865-6","volume":"35","author":"T Sasaki","year":"2016","unstructured":"Sasaki, T. et al. Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients. Clin. Rheumatol. 35, 541\u2013545 (2016).","journal-title":"Clin. Rheumatol."},{"key":"374_CR126","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pupt.2011.01.016","volume":"24","author":"R Koike","year":"2011","unstructured":"Koike, R. et al. Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients. Pulm. Pharmacol. Ther. 24, 401\u2013406 (2011).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"374_CR127","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1159\/000351648","volume":"37","author":"N Issa","year":"2013","unstructured":"Issa, N. et al. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am. J. Nephrol. 37, 602\u2013612 (2013).","journal-title":"Am. J. Nephrol."},{"key":"374_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013294","volume":"5","author":"O Morteau","year":"2010","unstructured":"Morteau, O. et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS One 5, e13294 (2010).","journal-title":"PLoS One"},{"key":"374_CR129","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/ndt\/gfg594","volume":"19","author":"M Tiefenthaler","year":"2004","unstructured":"Tiefenthaler, M. et al. In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. Nephrol. Dial. Transplant. 19, 553\u2013560 (2004).","journal-title":"Nephrol. Dial. Transplant."},{"key":"374_CR130","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.intimp.2014.05.004","volume":"21","author":"Y Ren","year":"2014","unstructured":"Ren, Y. et al. Tolerogenic dendritic cells modified by tacrolimus suppress CD4+ T-cell proliferation and inhibit collagen-induced arthritis in mice. Int. Immunopharmacol. 21, 247\u2013254 (2014).","journal-title":"Int. Immunopharmacol."},{"key":"374_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170806","volume":"12","author":"NM Kannegieter","year":"2017","unstructured":"Kannegieter, N. M. et al. The effect of tacrolimus and mycophenolic acid on CD14+ monocyte activation and function. PLoS One 12, e0170806 (2017).","journal-title":"PLoS One"},{"key":"374_CR132","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/keh325","volume":"43","author":"CE Lampropoulos","year":"2004","unstructured":"Lampropoulos, C. E. et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology 43, 1383\u20131385 (2004).","journal-title":"Rheumatology"},{"key":"374_CR133","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","volume":"75","author":"CC Mok","year":"2016","unstructured":"Mok, C. C. et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 75, 30\u201336 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"374_CR134","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","volume":"162","author":"Z Liu","year":"2015","unstructured":"Liu, Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18\u201326 (2015).","journal-title":"Ann. Intern. Med."},{"key":"374_CR135","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0961203318758505","volume":"27","author":"CB Choi","year":"2018","unstructured":"Choi, C. B. et al. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus 27, 1007\u20131011 (2018).","journal-title":"Lupus"},{"key":"374_CR136","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","volume":"18","author":"T Barba","year":"2019","unstructured":"Barba, T. et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun. Rev. 18, 113\u2013122 (2019).","journal-title":"Autoimmun. Rev."},{"key":"374_CR137","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","volume":"54","author":"T Kurita","year":"2015","unstructured":"Kurita, T. et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 54, 39\u201344 (2015).","journal-title":"Rheumatology"},{"key":"374_CR138","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03865888 (2019)."},{"key":"374_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00504348 (2017)."},{"key":"374_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01410747 (2019)."},{"key":"374_CR141","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1111\/1756-185X.13731","volume":"22","author":"M Suzuki","year":"2019","unstructured":"Suzuki, M. et al. Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: a retrospective cohort study. Int. J. Rheum. Dis. 22, 2199\u20132205 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"374_CR142","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/1756-185X.13521","volume":"22","author":"K Shin","year":"2019","unstructured":"Shin, K. et al. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. Int. J. Rheum. Dis. 22, 1115\u20131122 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"374_CR143","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/1759720X11419038","volume":"3","author":"S Dutta","year":"2011","unstructured":"Dutta, S. & Ahmad, Y. The efficacy and safety of tacrolimus in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 3, 283\u2013291 (2011).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"374_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03737708 (2019)."},{"key":"374_CR145","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02837978 (2019)."},{"key":"374_CR146","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/j.1600-6143.2010.03256.x","volume":"10","author":"BK Kr\u00e4mer","year":"2010","unstructured":"Kr\u00e4mer, B. K. et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am. J. Transplant. 10, 2632\u20132643 (2010).","journal-title":"Am. J. Transplant."},{"key":"374_CR147","doi-asserted-by":"publisher","unstructured":"Cattral, M. et al. Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients. Clin. Transplant. https:\/\/doi.org\/10.1111\/ctr.13180 (2018).","DOI":"10.1111\/ctr.13180"},{"key":"374_CR148","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/FTD.0000000000000503","volume":"40","author":"P Marquet","year":"2018","unstructured":"Marquet, P. et al. Pharmacokinetic therapeutic drug monitoring of advagraf in more than 500 adult renal transplant patients, using an expert system online. Ther. Drug Monit. 40, 285\u2013291 (2018).","journal-title":"Ther. Drug Monit."},{"key":"374_CR149","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2147\/PPA.S165101","volume":"12","author":"LA Anghel","year":"2018","unstructured":"Anghel, L. A. et al. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer. Adherence 12, 1151\u20131166 (2018).","journal-title":"Patient Prefer. Adherence"},{"key":"374_CR150","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3899\/jrheum.180507","volume":"45","author":"DYH Yap","year":"2018","unstructured":"Yap, D. Y. H. et al. Longterm data on sirolimus treatment in patients with Lupus Nephritis. J. Rheumatol. 45, 1663\u20131670 (2018).","journal-title":"J. Rheumatol."},{"key":"374_CR151","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/ard.2007.078808","volume":"67","author":"GA Bruyn","year":"2008","unstructured":"Bruyn, G. A. et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann. Rheum. Dis. 67, 1090\u20131095 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"374_CR152","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.transproceed.2015.12.039","volume":"48","author":"A Solazzo","year":"2016","unstructured":"Solazzo, A. et al. Interstitial lung disease after kidney transplantation and the role of everolimus. Transpl. Proc. 48, 349\u2013351 (2016).","journal-title":"Transpl. Proc."},{"key":"374_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07858-8","volume":"10","author":"HV Woodcock","year":"2019","unstructured":"Woodcock, H. V. et al. The mTORC1\/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nat. Commun. 10, 6 (2019).","journal-title":"Nat. Commun."},{"key":"374_CR154","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000701","volume":"5","author":"SLM Blokland","year":"2019","unstructured":"Blokland, S. L. M. et al. Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sj\u00f6gren\u2019s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? RMD Open 5, e000701 (2019).","journal-title":"RMD Open"},{"key":"374_CR155","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","volume":"78","author":"N Vazirpanah","year":"2019","unstructured":"Vazirpanah, N. et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann. Rheum. Dis. 78, 663\u2013671 (2019).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0374-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:21:30Z","timestamp":1684606890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0374-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":155,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0374-8","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"15 January 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.v.-L. declares that he has received honoraria from Arxx Tx, Eli Lilly, Gesyntha, Leadiant, Roche and Sanofi-Genzyme, and grants from Astra Zeneca, MSD, Roche and Thermofisher, unrelated to the topic of this work. J.C.A.B. declares that he has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}